Results 181 to 190 of about 7,679 (193)

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

Lancet, The, 2012
Hector Ortega, Ian Pavord, Eugene Bleecker   +2 more
exaly  

Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study

Clinical Therapeutics, 2019
Robert Price, Guy Brusselle, Frank Albers   +2 more
exaly  

Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab

American Journal of Respiratory and Critical Care Medicine, 2018
Nicola Lavigne, Parameswaran Nair, Manali Mukherjee   +2 more
exaly  

<p>Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease</p>

International Journal of COPD, 2019
Takudzwa Mkorombindo, Mark Dransfield
exaly  

Mepolizumab in eosinophilic disorders

Expert Review of Clinical Immunology, 2011
Philip E Putnam, J Pablo Abonia
exaly  

Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma

Journal of Allergy and Clinical Immunology, 2017
Pranabashis Haldar, Ian Pavord, Eugene Bleecker   +2 more
exaly  

Mepolizumab—a novel option for the treatment of hypereosinophilic syndrome in childhood

Pediatric Allergy and Immunology, 2018
Carsten Schwarz, Carsten Schwarz
exaly  

The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma

Allergy: European Journal of Allergy and Clinical Immunology, 2019
Robert Price, Frank Albers
exaly  

Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma

Respiratory Medicine, 2019
Namhee Kwon, Frank Albers, Santiago Quirce   +2 more
exaly  

Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment

Allergy: European Journal of Allergy and Clinical Immunology, 2016
exaly